Pfizer will end development of daily anti-obesity pill due to liver injury

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug. The patient did not experience any symptoms, and the injury resolved after discontinuation of the drug, Pfizer said in a statement. After reviewing all...